GRAIL secures $110 million in equity from Samsung for international expansion of Galleri cancer detection test

GRAIL has closed a $110 million equity investment from Samsung affiliates, giving the cancer detection company fresh capital as it works to win wider adoption for Galleri, its blood-based multi-cancer early detection test, and take the product into new markets outside the United States.

The financing comes at a key moment for GRAIL. The Menlo Park-based company is trying to do two things at once: push Galleri through the slow grind of U.S. regulatory and reimbursement processes, and build an international commercial footprint for a test it hopes can change how cancer is caught. Samsung’s investment does more than add cash to the balance sheet. It ties one of South Korea’s largest conglomerates more closely to GRAIL’s plan to sell Galleri in Asia.

Under the deal, Samsung entities, including Samsung C&T Corporation, bought GRAIL common stock at $70.05 per share, for a total investment of $110 million. GRAIL said the financing supports its growth plans and international expansion efforts.

“This investment from the Samsung entities further strengthens our balance sheet and extends our cash runway as we advance key priorities, including securing regulatory approval and reimbursement for Galleri® in the United States and expanding access to multi-cancer early detection internationally,” said Aaron Freidin, Chief Financial Officer of GRAIL. “We are pleased to complete this financing and look forward to deepening our strategic collaboration with Samsung as we work to bring Galleri to patients in Asia.”

That Asia piece is where the deal gets more interesting. GRAIL and Samsung C&T have already said they plan to work together to commercialize Galleri in South Korea, with room to expand into Japan and Singapore if regulatory approvals fall into place. For now, initial testing will still be run through GRAIL’s clinical laboratory in Research Triangle Park, North Carolina.

The partnership gives GRAIL more than a financial backer. Samsung C&T is a sprawling business with operations across construction, trading, fashion, and resorts, and it has been building a bigger presence in biopharma and life sciences through a series of investments. For GRAIL, that creates a potential entry point into Asian healthcare markets that can be difficult for U.S. companies to crack on their own.

“GRAIL is at a pivotal moment in its mission to transform early cancer detection. This investment in GRAIL, together with the strategic business collaboration, represents a significant milestone in advancing Samsung C&T’s vision of expanding access to cancer early detection. We are excited to bring the benefits of innovative screening technologies to more people in South Korea and Asia, and believe this partnership will bring us one step closer to GRAIL and Samsung C&T’s shared goal of transforming cancer care through earlier detection,” said Jaywoo Kim, Executive Vice President of Life Science Business at Samsung C&T.

GRAIL has spent years pitching Galleri as a way to spot multiple deadly cancers earlier through a single blood draw. The test uses targeted methylation sequencing, large clinical datasets, and machine learning to detect cancer signals in the bloodstream and predict where the cancer may have originated. That pitch has helped make GRAIL one of the most closely watched biotech companies in cancer screening, though the road from scientific promise to routine clinical use remains a hard one.

Galleri cancer detection test (Courtesy: GRAIL)

The company still faces the same big questions hanging over the multi-cancer early detection market: whether regulators will fully back the category, whether insurers will pay for it at scale, and how much real-world evidence companies will need to demonstrate that earlier detection leads to better patient outcomes. Galleri has attracted attention as one of the best-known products in the space, but broader adoption will depend on more than technology. It will hinge on clinical validation, physician trust, reimbursement, and the economics of rolling out large-scale screening.

Samsung’s investment does not settle those questions, but it does buy GRAIL more time and a stronger strategic foothold in Asia as the company tries to turn Galleri from a closely watched test into a global cancer screening business.